The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/118044

Please be advised that this information was generated on 2017-11-20 and may be subject to change.
Azole-Resistant Aspergillus fumigatus, Iran

To the Editor: Aspergillus fumigatus causes a variety of diseases in humans. The drugs recommended for treatment of Aspergillus diseases are the mold-active azole antifungal drugs (1). However, a wide range of mutations in A. fumigatus confer azole resistance, which commonly involves modifications in the cyp51A gene (2), the target for azole antifungal drugs.

Azole resistance is thought to be selected for as a result of patient therapy or exposure toazole compounds in the environment; resistance in clinical A. fumigatus isolates has been increasingly reported in several European countries, Asia, and the United States (3–7). The most frequently reported resistance mechanism is a 34-bp tandem repeat (TR<sub>34</sub>) in combination with a substitution at codon 98 (TR<sub>34</sub>/L98H) (4); this mechanism is believed to have been selected for through environmental exposure to azole fungicides.

Because routine in vitro susceptibility testing of clinical Aspergillus isolates is not common in many centers worldwide, the prevalence of azole resistance might be underestimated. We investigated the prevalence of azole resistance in clinical A. fumigatus isolates stored for 6 years (2003–2009) at Tehran University Mycology Reference Centre and Islamic Azad University, Ardabil Branch, Iran.

We investigated 124 clinical A. fumigatus isolates obtained from patients with Aspergillus diseases (online Technical Appendix Table 1). Most isolates were identified as A. fumigatus (89%), the rest were identified as A. flavus and A. niger (5%) and 2 isolates were not identified. The MICs of azole antifungals were obtained using an Etest strip. All azole MICs were determined as a 4-fold dilution from 2 mg/L. All azole MICs were performed on 3 separate plates, and each isolates were tested at least 3 times.

We first tested the TR<sub>34</sub> L98H isolate had been recovered from a short tandem repeat (TR<sub>34</sub>) isolate from an infected patient in Iran. The first TR<sub>34</sub>/L98H isolate had been recovered in 2005, which is relatively early compared with reported isolations in other countries (online Technical Appendix Table 2). Microsatellite typing of 6 short tandem repeat loci demonstrated identical patterns for 2 of the 3 azole-resistant isolates from Iran, but the TR<sub>34</sub>/L98H isolates from Iran did not cluster with those from the Netherlands and other European countries, indicating no close genetic relatedness (online Technical Appendix Figure).

The TR<sub>34</sub>/L98H azole resistance mechanism was first described in 1998 in the Netherlands; since then, its presence in clinical and environmental A. fumigatus isolates in multiple European countries and recently in Asia has been increasingly reported (online Technical Appendix Table 2) (3–7). In the study reported here, prevalence of azole resistance in clinical A. fumigatus isolates obtained from patients in Iran was 3.2%; most isolates exhibited the target for azole antifungal drugs.

Because routine in vitro susceptibility testing of clinical Aspergillus isolates is not common in many centers worldwide, the prevalence of azole resistance might be underestimated. We investigated the prevalence of azole resistance in clinical A. fumigatus isolates stored for 6 years (2003–2009) at Tehran University Mycology Reference Centre and Islamic Azad University, Ardabil Branch, Iran.

We investigated 124 clinical A. fumigatus isolates obtained from patients with Aspergillus diseases (online Technical Appendix Table 1). Most isolates were identified as A. fumigatus (89%), the rest were identified as A. flavus and A. niger (5%) and 2 isolates were not identified. The MICs of azole antifungals were obtained using an Etest strip. All azole MICs were determined as a 4-fold dilution from 2 mg/L. All azole MICs were performed on 3 separate plates, and each isolates were tested at least 3 times.

We first tested the TR<sub>34</sub> L98H isolate had been recovered from a short tandem repeat (TR<sub>34</sub>) isolate from an infected patient in Iran. The first TR<sub>34</sub>/L98H isolate had been recovered in 2005, which is relatively early compared with reported isolations in other countries (online Technical Appendix Table 2). Microsatellite typing of 6 short tandem repeat loci demonstrated identical patterns for 2 of the 3 azole-resistant isolates from Iran, but the TR<sub>34</sub>/L98H isolates from Iran did not cluster with those from the Netherlands and other European countries, indicating no close genetic relatedness (online Technical Appendix Figure).

The TR<sub>34</sub>/L98H azole resistance mechanism was first described in 1998 in the Netherlands; since then, its presence in clinical and environmental A. fumigatus isolates in multiple European countries and recently in Asia has been increasingly reported (online Technical Appendix Table 2) (3–7). In the study reported here, prevalence of azole resistance in clinical A. fumigatus isolates obtained from patients in Iran was 3.2%; most isolates exhibited the TR<sub>34</sub>/L98H resistance mechanism. The fact that the first TR<sub>34</sub>/L98H isolate was found relatively early, in 2005, underscores the possibility that prevalence...
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 19, No. 5, May 2013

of azole resistance might be underestimated in many countries because in vitro susceptibility testing of *A. fumigatus* is not routinely performed.

Microsatellite genotypic analysis of *A. fumigatus* isolates from the Netherlands and various European countries showed that the genetic diversity of TR$_{L98H}$/L98H isolates is lower than that of wild-type controls (8). It has been suggested that TR$_{L98H}$/L98H isolates might have a common ancestor that developed locally and subsequently migrated across Europe. In contrast, genotyping of TR$_{L98H}$/L98H originating from India suggested a different dynamic; all environmental and clinical TR$_{L98H}$/L98H isolates from India shared the same multilocus microsatellite genotype not found in any other analyzed samples, from within India or from the Netherlands, France, Germany, or the People’s Republic of China (9). The molecular epidemiology of the TR$_{L98H}$/L98H isolates from Iran suggests that they cluster apart from the European isolates, indicating that migration from Europe to Iran, or vice versa, is unlikely. Genotyping of more TR$_{L98H}$/L98H isolates from the Middle East and comparison with those from India would enhance understanding of the origin and geographic spread of TR$_{L98H}$/L98H.

Our study indicates that TR$_{L98H}$/L98H was in Iran in 2005; this finding adds to the growing list of regions where acquired resistance in *A. fumigatus* of environmental origin is documented. From a global perspective, fungicide use is second highest in the Asia–Pacific regions (24%), preceded only by western Europe (37%) (10).

For a bettering understand of the scale of this emerging public health problem and for insight into the dynamics of geographic migration, surveys of fungal culture collections for TR$_{L98H}$/L98H and molecular typing studies are warranted. These data would be useful not only for clinical management of *Aspergillus* diseases but also for enabling policy makers to develop strategies that prevent resistance selection by the environmental route.

Acknowledgments
We thank Jacques F. Meis and Ferry Hagen for performing additional real-time PCRs to screen mutations in 4 azole-resistant isolates.

This work was supported in part by a research grant from the Faculty of Medicine and Medical Sciences, Islamic Azad University, Ardabil Branch, Iran, and the School of Hygiene & Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran.

S.J.M., E.Z., M.T.H., J.Z., and W.J.G.M. have no conflicts of interest. S.S. received a research grant from the Faculty of Medicine and Medical Sciences, Islamic Azad University, Ardabil Branch, Iran. J.W.M. and P.E.V. have served as consultants to and have received research grants from Astellas, Basilea, Gilead Sciences, Pfizer, and Merck.

Seyedmojtaba Seyedmousavi, Seyed Jamal Hashemi, Ensieh Zibafar, Jan Zoll, Mohammad T. Hedayati, Johan W. Mouton, Willem J.G. Melchers, and Paul E. Verweij

Author affiliations: Mazandaran University of Medical Sciences, Sari, Iran (S. Seyedmousavi, M.T. Hedayati); Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands (S. Seyedmousavi, J.W. Mouton, W.J.G. Melchers, P.E. Verweij); Nijmegen Institute for Infection, Inflammation and Immunity, Nijmegen (S. Seyedmousavi, J.W. Mouton, W.J.G. Melchers, P.E. Verweij); and Tehran University of Medical Sciences, Tehran, Iran (S.J. Hashemi, E. Zibafar) Radboud University Nijmegen Medical Center (Jan Zoll)

DOI: http://dx.doi.org/10.3201/eid1905.130075

References


Table. Characteristics of 4 azole-resistant clinical *Aspergillus fumigatus* isolates, Iran*

<table>
<thead>
<tr>
<th>Isolate</th>
<th>Underlying disease</th>
<th>Previous azole exposure</th>
<th>34-bp tandem repeat†</th>
<th>Amino acid substitution in cyp51A gene‡</th>
<th>MIC, mg/L</th>
<th>Amphotericin B</th>
<th>Itraconazole</th>
<th>Voriconazole</th>
<th>Posaconazole</th>
</tr>
</thead>
<tbody>
<tr>
<td>T-IR-AF 12</td>
<td>CPA</td>
<td>Yes</td>
<td>Positive</td>
<td>L98H</td>
<td>0.5</td>
<td>≥16</td>
<td>4.0</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>T-IR-AF 17</td>
<td>CPA</td>
<td>No</td>
<td>Positive</td>
<td>L98H</td>
<td>0.5</td>
<td>≥16</td>
<td>4.0</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>T-IR-AF 433</td>
<td>CPA</td>
<td>Yes</td>
<td>Negative</td>
<td>ND</td>
<td>0.5</td>
<td>≥16</td>
<td>8.0</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>T-IR-AF 890</td>
<td>ABPA</td>
<td>No</td>
<td>Positive</td>
<td>L98H</td>
<td>0.5</td>
<td>≥16</td>
<td>8.0</td>
<td>0.25</td>
<td></td>
</tr>
</tbody>
</table>

*CPA, chronic pulmonary aspergillosis; ND, not detected; ABPA, allergic bronchopulmonary aspergillosis.
†34-bp tandem repeat in the promoter region of CYP51A gene.
‡The numbers indicate the position at which an amino acid change occurs. Nucleotides are numbered from the translation start codon ATG of cyp51A.
To the Editor: Q fever is a zoonosis caused by the bacterium Coxiella burnetii. The Q fever outbreak in the Netherlands affected ~4,000 humans during 2007–2010 (1). In this outbreak, 1 genotype of C. burnetii appeared to be responsible for abortions in small ruminants and for clinical disease in humans (2,3). However, little is known about the outbreak genotype and the prevalence of C. burnetii in possible additional reservoirs for Human Q fever (i.e., cats, dogs, horses, sheep, and cattle) in the Netherlands.

We aimed to search for possible additional reservoirs for human Q fever in the Netherlands. Placentas from 15 cats, 54 dogs, and 31 horses were collected in 2011 at 5 veterinary practices. Placentas were collected by targeted sampling at breeding facilities and during parturition with veterinary assistance. In addition, 27 ovine, 11 caprine, 16 porcine, 8 equine, and 139 bovine placentas (originating from aborting animals from throughout the Netherlands that were submitted in 2011 to investigate the abortion cause) were included in the study. Samples were stored at −20°C before testing.

DNA was extracted from the allantochorion of the placenta and analyzed as described (2). Samples with sufficient DNA load (cycle threshold [C] value <32) were typed by using 2 multilocus variable-number tandem-repeat analyses (MLVA) genotyping methods (MLVA-12 and MLVA-6), and the multispacer sequence typing method (3–5). Two C. burnetii strains from the Netherlands representing the outbreak genotype (X09003262, 3345937) and the Nine Mile RSA 493 were included as reference. For prevalence calculations, the Netherlands was divided in a southern part, comprising the Q fever hot spot area of notified cases in humans and small ruminants during the 2007–2010 epidemic (1,6), and a northern part, comprising the rest of the country.

C. burnetii DNA was not detected in placentas from cats, goats, or pigs. C. burnetii DNA was detected in 4 (7% [95% CI 0.4–14.4]) of 54 canine placentas; 3 from the north and 1 from the south of the Netherlands. C. burnetii DNA was detected in 3 (8% [95% CI 0.0–16.1]) of 39 equine placentas, all from the north of the country, without known abortion history. C. burnetii DNA was detected in 7 (26% [95% CI 9.4–42.5]) of 27 ovine and in 33 (24% [95% CI 16.7–30.8]) of 139 bovine placentas. The prevalence of C. burnetii DNA–positive ovine and bovine placentas from the north and the south did not differ significantly.

The C. burnetii DNA load in the placentas from dogs (C value 37.4–38.0) and horses (C value 35.4–37.4) was too low to be suitable for genotyping. Typing of 1 positive sheep sample resulted in an incomplete genotype, which is related to the outbreak genotype (sheep 192, Figure). Seven of the 33 C. burnetii DNA–positive bovine placentas were suitable for typing. One sample had a genotype similar to the outbreak genotype (2,3). Six other samples revealed a (partial) genotype related to bovine genotypes from the Netherlands (2,5,7), including a novel one. MLVA-6 and multispacer sequence typing results were consistent with the MLVA-12 results (Figure).

Results give no indication for major reservoirs of C. burnetii in cats, goats, and pigs in the Netherlands in 2011. However, the low numbers of placentas may have biased the results. Dogs and horses should be considered as reservoirs for C. burnetii. The detection of C. burnetii DNA–positive placentas in dogs and horses in the northern part of the country indicates the presence of a true reservoir rather than a spillover effect from the contaminated environment in the south. This observation is consistent with a reported seroprevalence of 13% in dogs in the Netherlands in 1992 (1). Until now, horses had been discussed as a risk factor in the Q fever outbreak in the Netherlands (8).

Prevalence data from sheep and cattle suggest that C. burnetii is present in placentas in 25% of the abortion cases in these species. Presence of the outbreak genotype of C. burnetii in sheep has been observed (2,5), indicating sheep are a reservoir for Q fe-